Header Logo

Connection

LORETTA NASTOUPIL to Lymphoma, Large B-Cell, Diffuse

Back to Details
This is a "connection" page, showing publications LORETTA NASTOUPIL has written about Lymphoma, Large B-Cell, Diffuse.
LORETTA NASTOUPIL
Connection Strength
6.932
Lymphoma, Large B-Cell, Diffuse
  1. Management of aggressive lymphoma after CAR T-cell therapy failure. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):364-369.
    View in: PubMed
    Score: 0.446
  2. Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):903-913.
    View in: PubMed
    Score: 0.417
  3. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):2871-2883.
    View in: PubMed
    Score: 0.353
  4. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 09 20; 38(27):3119-3128.
    View in: PubMed
    Score: 0.349
  5. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma. 2018 12; 59(12):2896-2903.
    View in: PubMed
    Score: 0.302
  6. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151.
    View in: PubMed
    Score: 0.266
  7. Socioeconomic disparities in lymphoma. Blood. 2014 Jun 05; 123(23):3530-1.
    View in: PubMed
    Score: 0.231
  8. Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park). 2012 May; 26(5):488-95.
    View in: PubMed
    Score: 0.200
  9. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8(4):1042-1050.
    View in: PubMed
    Score: 0.113
  10. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023 12 28; 142(26):2327-2331.
    View in: PubMed
    Score: 0.112
  11. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 2023 11 14; 7(21):6785-6789.
    View in: PubMed
    Score: 0.111
  12. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 11 09; 16(1):111.
    View in: PubMed
    Score: 0.111
  13. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023 09 21; 142(12):1047-1055.
    View in: PubMed
    Score: 0.110
  14. A single-cell atlas of CD19 chimeric antigen receptor T?cells. Cancer Cell. 2023 11 13; 41(11):1835-1837.
    View in: PubMed
    Score: 0.110
  15. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.
    View in: PubMed
    Score: 0.110
  16. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 07 25; 7(14):3516-3529.
    View in: PubMed
    Score: 0.109
  17. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
    View in: PubMed
    Score: 0.108
  18. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 09; 29(9):548-555.
    View in: PubMed
    Score: 0.108
  19. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145.
    View in: PubMed
    Score: 0.107
  20. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica. 2023 04 01; 108(4):1163-1167.
    View in: PubMed
    Score: 0.106
  21. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med. 2022 11 15; 3(11):100720.
    View in: PubMed
    Score: 0.104
  22. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia. 2022 Nov; 36(11):2669-2677.
    View in: PubMed
    Score: 0.103
  23. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.
    View in: PubMed
    Score: 0.102
  24. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.
    View in: PubMed
    Score: 0.102
  25. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755.
    View in: PubMed
    Score: 0.102
  26. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515.
    View in: PubMed
    Score: 0.102
  27. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676.
    View in: PubMed
    Score: 0.101
  28. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022 07 01; 107(7):1555-1566.
    View in: PubMed
    Score: 0.101
  29. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):753-759.
    View in: PubMed
    Score: 0.100
  30. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2867-2871.
    View in: PubMed
    Score: 0.100
  31. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022 03 01; 107(3):690-701.
    View in: PubMed
    Score: 0.099
  32. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672.
    View in: PubMed
    Score: 0.096
  33. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2022 01; 63(1):74-83.
    View in: PubMed
    Score: 0.095
  34. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving =3 therapy lines in post-CAR-T era. Curr Med Res Opin. 2021 10; 37(10):1789-1798.
    View in: PubMed
    Score: 0.095
  35. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
    View in: PubMed
    Score: 0.095
  36. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021 06 10; 137(23):3272-3276.
    View in: PubMed
    Score: 0.094
  37. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.
    View in: PubMed
    Score: 0.093
  38. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 04 01; 137(13):1832-1835.
    View in: PubMed
    Score: 0.093
  39. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5.
    View in: PubMed
    Score: 0.092
  40. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
    View in: PubMed
    Score: 0.091
  41. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020 12; 26(12):1878-1887.
    View in: PubMed
    Score: 0.090
  42. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336.
    View in: PubMed
    Score: 0.083
  43. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019 06 27; 133(26):2800-2802.
    View in: PubMed
    Score: 0.081
  44. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61.
    View in: PubMed
    Score: 0.078
  45. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154.
    View in: PubMed
    Score: 0.074
  46. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
    View in: PubMed
    Score: 0.071
  47. Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. South Med J. 2016 10; 109(10):606-614.
    View in: PubMed
    Score: 0.068
  48. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299.
    View in: PubMed
    Score: 0.067
  49. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016; 57(4):842-51.
    View in: PubMed
    Score: 0.064
  50. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.061
  51. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4.
    View in: PubMed
    Score: 0.061
  52. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015 Jun 01; 121(11):1800-8.
    View in: PubMed
    Score: 0.061
  53. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):460-467.e2.
    View in: PubMed
    Score: 0.058
  54. Insurance status is related to diffuse large B-cell lymphoma survival. Cancer. 2014 Apr 15; 120(8):1220-7.
    View in: PubMed
    Score: 0.056
  55. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):569-77.
    View in: PubMed
    Score: 0.053
  56. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1520-30.
    View in: PubMed
    Score: 0.051
  57. HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):303-311.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.